HIV Preexposure Prophylaxis, by Race and Ethnicity - United States, 2014-2016.

Huang YA, Zhu W, Smith DK, Harris N, Hoover KW. · 2018

Read HIV Preexposure Prophylaxis, by Race and Ethnicity - United States, 2014-2016. by Huang YA, Zhu W, Smith DK, Harris N, Hoover KW. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6193685.txt.

Description

Huang and co-authors report in Morbidity and Mortality Weekly Report on HIV preexposure prophylaxis use in the United States, 2014 to 2016. PrEP is a daily pill of antiretroviral drugs that strongly prevents HIV infection. The approved drug combines tenofovir and emtricitabine. It is meant for people whose behavior puts them at high risk.

CDC analysts used a national prescription database to count PrEP users. The yearly number aged 16 and over rose 470 percent, from 13,748 in 2014 to 78,360 in 2016. The report describes users by sex and by race and ethnicity. It gives public health a baseline for judging whether PrEP reaches those who need it most.

Catalog record

CREATORHuang YA, Zhu W, Smith DK, Harris N, Hoover KW.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE15 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6193685

Browse the full library · About the Tower of Babel